Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Current Leases (2019 - 2025)

Immunocore Holdings' Current Leases history spans 4 years, with the latest figure at $2.0 million for Q4 2025.

  • For Q4 2025, Current Leases rose 29.67% year-over-year to $2.0 million; the TTM value through Dec 2025 reached $2.0 million, up 29.67%, while the annual FY2025 figure was $2.0 million, 29.67% up from the prior year.
  • Current Leases for Q4 2025 was $2.0 million at Immunocore Holdings, up from $1.9 million in the prior quarter.
  • Across five years, Current Leases topped out at $2.0 million in Q4 2025 and bottomed at $1.1 million in Q3 2024.
  • The 4-year median for Current Leases is $1.6 million (2024), against an average of $1.6 million.
  • The largest annual shift saw Current Leases dropped 26.25% in 2023 before it soared 71.19% in 2025.
  • A 4-year view of Current Leases shows it stood at $1.9 million in 2022, then fell by 26.25% to $1.4 million in 2023, then rose by 11.46% to $1.5 million in 2024, then increased by 29.67% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Current Leases are $2.0 million (Q4 2025), $1.9 million (Q3 2025), and $1.8 million (Q2 2025).